LRRK2 Kinase Inhibition Attenuates Neuroinflammation and Cytotoxicity in Animal Models of Alzheimer’s and Parkinson’s Disease-Related Neuroinflammation
Cells · 06.07.2023 · 12 (13) · 1799
DOI: 10.3390/cells12131799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 06.07.2023. Verfasst von Veronica Mutti und 6 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy. Hauptthemen laut MEDLINE: Parkinson Disease, Alzheimer Disease. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Italian Ministry of Health.
Themen: Demenz
Abstract (Originalsprache)
Chronic neuroinflammation plays a crucial role in the progression of several neurodegenerative diseases (NDDs), including Parkinson’s disease (PD) and Alzheimer’s disease (AD). Intriguingly, in the last decade, leucine-rich repeat kinase-2 (LRRK2), a gene mutated in familial and sporadic PD, was revealed as a key mediator of neuroinflammation. Therefore, the anti-inflammatory properties of LRRK2 inhibitors have started to be considered as a disease-modifying treatment for PD; however, to date, there is little evidence on the beneficial effects of targeting LRRK2-related neuroinflammation in preclinical models. In this study, we further validated LRRK2 kinase modulation as a pharmacological intervention in preclinical models of AD- and PD-related neuroinflammation. Specifically, we reported that LRRK2 kinase inhibition with MLi2 and PF-06447475 (PF) molecules attenuated neuroinflammation, gliosis and cytotoxicity in mice with intracerebral injection of Aβ1-42 fibrils or α-syn preformed fibrils (pffs). Moreover, for the first time in vivo, we showed that LRRK2 kinase activity participates in AD-related neuroinflammation and therefore might contribute to AD pathogenesis. Overall, our findings added evidence on the anti-inflammatory effects of LRRK2 kinase inhibition in preclinical models and indicate that targeting LRRK2 activity could be a disease-modifying treatment for NDDs with an inflammatory component.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, 25125 Brescia, Italy.
- Biology and Genetics Unit, Department of Molecular and Translational Medicine, University of Brescia, 25123 Brescia, Italy.
- Human Anatomy Unit, Department of Biomedical Sciences and Biotechnologies, University of Brescia, 25123 Brescia, Italy.
ORCID-Profile: Veronica Mutti, Giulia Carini, Alice Filippini
Förderung
- Ministero della Salute
- Italian Ministry of Health
Zitieren
APA
Mutti, V., Carini, G., Filippini, A., Castrezzati, S., Giugno, L., Gennarelli, M., & Russo, I. (2023). LRRK2 Kinase Inhibition Attenuates Neuroinflammation and Cytotoxicity in Animal Models of Alzheimer’s and Parkinson’s Disease-Related Neuroinflammation. Cells, 12(13), 1799. https://doi.org/10.3390/cells12131799
Vancouver
Mutti V, Carini G, Filippini A, Castrezzati S, Giugno L, Gennarelli M, et al. LRRK2 Kinase Inhibition Attenuates Neuroinflammation and Cytotoxicity in Animal Models of Alzheimer’s and Parkinson’s Disease-Related Neuroinflammation. Cells. 2023;12(13):1799. doi:10.3390/cells12131799
BibTeX
@article{Mutti2023,
author = {Mutti, Veronica and Carini, Giulia and Filippini, Alice and Castrezzati, Stefania and Giugno, Lorena and Gennarelli, Massimo and Russo, Isabella},
title = {LRRK2 Kinase Inhibition Attenuates Neuroinflammation and Cytotoxicity in Animal Models of Alzheimer’s and Parkinson’s Disease-Related Neuroinflammation},
journal = {Cells},
year = {2023},
volume = {12},
number = {13},
pages = {1799},
doi = {10.3390/cells12131799}
}
EUVIMED